OncoSignal
Live from Open Targets Platform, fetched 2026-11-11 23:15 UTC. Every row links to its source record.

BAP1 BRCA1 associated deubiquitinase 1

ENSG00000163930 · protein coding · Open Targets profile

Deubiquitinating enzyme that plays a key role in chromatin by mediating deubiquitination of histone H2A and HCFC1 (PubMed:12485996, PubMed:18757409, PubMed:20436459, PubMed:25451922, PubMed:35051358). Catalytic component of the polycomb repressive deubiquitinase (PR-DUB) complex, a complex that specifically mediates deubiquitination of histone H2A monoubiquitinated at 'Lys-120' (H2AK119ub1) (PubMed:20436459, PubMed:25451922, PubMed:30664650, PubMed:35051358). Does not deubiquitinate monoubiquitinated histone H2B (PubMed:20436459, PubMed:30664650). The PR-DUB complex is an epigenetic regulator of gene expression and acts as a transcriptional coactivator, affecting genes involved in development, cell communication, signaling, cell proliferation and cell viability (PubMed:20805357, PubMed:30664650, PubMed:36180891). Antagonizes PRC1 mediated H2AK119ub1 monoubiquitination (PubMed:30664650). As part of the PR-DUB complex, associates with chromatin enriched in histone marks H3K4me1, H3K4me3, and H3K27Ac, but not in H3K27me3 (PubMed:36180891). Recruited to specific gene-regulatory regions by YY1 (PubMed:20805357). Acts as a regulator of cell growth by mediating deubiquitination of HCFC1 N- terminal and C-terminal chains, with some specificity toward 'Lys-48'- linked polyubiquitin chains compared to 'Lys-63'-linked polyubiquitin chains (PubMed:19188440, PubMed:19815555). Deubiquitination of HCFC1 does not lead to increase stability of HCFC1 (PubMed:19188440, PubMed:19815555). Interferes with the BRCA1 and BARD1 heterodimer activity by inhibiting their ability to mediate ubiquitination and autoubiquitination (PubMed:19117993). It however does not mediate deubiquitination of BRCA1 and BARD1 (PubMed:19117993). Able to mediate autodeubiquitination via intramolecular interactions to counteract monoubiquitination at the nuclear localization signal (NLS), thereby protecting it from cytoplasmic sequestration (PubMed:24703950). Negatively regulates epithelial-mesenchymal transition (EMT) of trophoblast stem cells during placental development by regulating genes involved in epithelial cell integrity, cell adhesion and cytoskeletal organization (PubMed:34170818). {ECO:0000269|PubMed:12485996, ECO:0000269|PubMed:18757409, ECO:0000269|PubMed:19117993, ECO:0000269|PubMed:19188440, ECO:0000269|PubMed:19815555, ECO:0000269|PubMed:20436459, ECO:0000269|PubMed:20805357, ECO:0000269|PubMed:24703950, ECO:0000269|PubMed:25451922, ECO:0000269|PubMed:30664650, ECO:0000269|PubMed:34170818, ECO:0000269|PubMed:35051358, ECO:0000269|PubMed:36180891}.

In 9 of 15 cancers, the evidence for BAP1 comes mainly from mutations found in tumours

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751BAP1-related tumor predisposition syndr…BAP1-related tumor predisposition syndromeBAP1-related tumor predisposition syndrome: germline 0.89uveal melanomauveal melanomauveal melanoma: somatic 0.60uveal melanoma: germline 0.56pleural mesotheliomapleural mesotheliomapleural mesothelioma: somatic 0.81pleural mesothelioma: germline 0.61clear cell renal carcinomaclear cell renal carcinomaclear cell renal carcinoma: somatic 0.76clear cell renal carcinoma: germline 0.43hereditary neoplastic syndromehereditary neoplastic syndromehereditary neoplastic syndrome: germline 0.95melanoma, uveal, susceptibility to, 2melanoma, uveal, susceptibility to, 2hepatocellular carcinomahepatocellular carcinomahepatocellular carcinoma: somatic 0.68cholangiocarcinomacholangiocarcinomacholangiocarcinoma: somatic 0.78malignant mesotheliomamalignant mesotheliomamalignant mesothelioma: somatic 0.30malignant mesothelioma: germline 0.61renal cell carcinomarenal cell carcinomarenal cell carcinoma: somatic 0.58cervical squamous cell carcinomacervical squamous cell carcinomacervical squamous cell carcinoma: somatic 0.58meningiomameningiomameningioma: germline 0.61peritoneal mesotheliomaperitoneal mesotheliomaperitoneal mesothelioma: somatic 0.61malignant epithelioid mesotheliomamalignant epithelioid mesotheliomamalignant epithelioid mesothelioma: somatic 0.61iris melanomairis melanomairis melanoma: germline 0.61

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

PROTAC
UniProt Ubiquitination, Database Ubiquitination, Half-life Data, Small Molecule Binder

gnomAD loss of function constraint: o/e 0.20714999735355377 (upper bound 0.31463000178337097). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of BAP1's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of BAP1's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.